Key facts
- This page summarizes Brian Piekos's Form 4 filing for Gemini Therapeutics, Inc. /DE (IRON).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Jan 2022, 08:01.
Brian Piekos - 13 Jan 2022 Form 4 Insider Report for Gemini Therapeutics, Inc. /DE (IRON)
- SEC form
- 4
- Accepted by SEC
- 14 Jan 2022, 08:01:21 UTC
- Prior SEC filing
- 20 Oct 2021
- Next SEC filing
- 02 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Piekos
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian Piekos filed Form 4 for Gemini Therapeutics, Inc. /DE (IRON) on 14 Jan 2022.
Change
- Previous filing in this sequence was filed on 20 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IRON
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +280,876
- Change %
- Price
- $0.000000
- Shares after
- 280,876
- Date
- 13 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 280,876
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock.
Footnote F2
These Restricted Stock Units shall vest on the one (1)-year anniversary of the date of grant.